Loading...

Albireo Pharma

DB:BDQM
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BDQM
DB
$370M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. The last earnings update was 49 days ago. More info.


Add to Portfolio Compare Print
  • Albireo Pharma has significant price volatility in the past 3 months.
BDQM Share Price and Events
7 Day Returns
-1.8%
DB:BDQM
-0.1%
DE Biotechs
1%
DE Market
1 Year Returns
10.3%
DB:BDQM
-7.4%
DE Biotechs
-5.6%
DE Market
BDQM Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Albireo Pharma (BDQM) -1.8% 11.5% 40.8% 10.3% - -
DE Biotechs -0.1% 6% -6.7% -7.4% 53.2% 11.6%
DE Market 1% 6.1% 8.4% -5.6% 10.9% 13.8%
1 Year Return vs Industry and Market
  • BDQM outperformed the Biotechs industry which returned -7.4% over the past year.
  • BDQM outperformed the Market in Germany which returned -5.6% over the past year.
Price Volatility
BDQM
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Albireo Pharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Albireo Pharma. This is due to cash flow or dividend data being unavailable. The share price is €27.44.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Albireo Pharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Albireo Pharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:BDQM PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-3.94
NasdaqCM:ALBO Share Price ** NasdaqCM (2019-04-24) in USD $30.8
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.73x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.72x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Albireo Pharma.

DB:BDQM PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:ALBO Share Price ÷ EPS (both in USD)

= 30.8 ÷ -3.94

-7.82x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Albireo Pharma is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Albireo Pharma is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Albireo Pharma's expected growth come at a high price?
Raw Data
DB:BDQM PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -7.82x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts
38%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Albireo Pharma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Albireo Pharma's assets?
Raw Data
DB:BDQM PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $10.25
NasdaqCM:ALBO Share Price * NasdaqCM (2019-04-24) in USD $30.8
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.72x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:BDQM PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:ALBO Share Price ÷ Book Value per Share (both in USD)

= 30.8 ÷ 10.25

3.01x

* Primary Listing of Albireo Pharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Albireo Pharma is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Albireo Pharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Albireo Pharma has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Albireo Pharma expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
38%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Albireo Pharma expected to grow at an attractive rate?
  • Albireo Pharma's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Albireo Pharma's earnings growth is expected to exceed the Germany market average.
  • Albireo Pharma's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:BDQM Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:BDQM Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts 38%
DB:BDQM Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts 54.5%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:BDQM Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:BDQM Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 228 100 6
2022-12-31 134 56 6
2021-12-31 57 -83 4
2020-12-31 20 -78 6
2019-12-31 6 -73 7
DB:BDQM Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 13 -27 -46
2018-09-30 12 -25 -35
2018-06-30 12 -20 -28
2018-03-31 11 -18 -19
2017-12-31 0 -28 -24
2017-09-30 3 -26 -31
2017-06-30 3 -25 -28
2017-03-31 11 -15 -20
2016-12-31 11 -9 -16
2016-09-30 13 -1 -5
2016-06-30 13 1 -4
2016-03-31 5 -5 -8

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Albireo Pharma's earnings are expected to grow significantly at over 20% yearly.
  • Albireo Pharma's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:BDQM Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below

All data from Albireo Pharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:BDQM Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 6.09 13.71 2.61 5.00
2022-12-31 6.38 6.38 6.38 1.00
2021-12-31 -5.70 -4.39 -7.48 5.00
2020-12-31 -5.40 -4.20 -7.10 8.00
2019-12-31 -5.78 -4.07 -7.05 8.00
DB:BDQM Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -3.94
2018-09-30 -3.23
2018-06-30 -2.73
2018-03-31 -2.16
2017-12-31 -3.12
2017-09-30 -4.62
2017-06-30 -6.29
2017-03-31 -7.20
2016-12-31 -13.19
2016-09-30 -4.00
2016-06-30 -1.78
2016-03-31 -2.71

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Albireo Pharma will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Albireo Pharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Albireo Pharma has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Albireo Pharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Albireo Pharma's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Albireo Pharma does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Albireo Pharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Albireo Pharma's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Albireo Pharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Albireo Pharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:BDQM Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 12.74 -46.11 18.46 31.33
2018-09-30 12.17 -35.30 17.24 25.80
2018-06-30 11.93 -27.79 17.10 19.37
2018-03-31 11.20 -19.36 16.57 15.93
2017-12-31 0.00 -24.41 15.64 12.60
2017-09-30 3.24 -30.58 15.53 10.30
2017-06-30 3.27 -28.10 13.01 9.29
2017-03-31 11.24 -19.78 12.26 9.11
2016-12-31 11.36 -16.35 10.29 7.96
2016-09-30 13.10 -4.65 8.38 7.82
2016-06-30 13.09 -3.62 8.11 7.22
2016-03-31 5.17 -7.88 5.47 5.82
2015-12-31 5.10 -6.77 4.56 5.54
2014-12-31 2.41 -6.40 2.11 6.58

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Albireo Pharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Albireo Pharma has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Albireo Pharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Albireo Pharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Albireo Pharma has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Albireo Pharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Albireo Pharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Albireo Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Albireo Pharma's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Albireo Pharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Albireo Pharma has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Albireo Pharma Company Filings, last reported 3 months ago.

DB:BDQM Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 122.64 0.00 163.89
2018-09-30 136.67 0.00 173.60
2018-06-30 149.45 0.00 183.23
2018-03-31 160.17 0.00 192.92
2017-12-31 65.25 0.00 53.23
2017-09-30 69.12 1.47 57.07
2017-06-30 75.25 1.93 62.60
2017-03-31 31.21 2.49 20.14
2016-12-31 36.95 3.08 29.93
2016-09-30 -13.30 6.91 1.72
2016-06-30 -9.21 7.31 6.25
2016-03-31 -8.22 7.38 5.12
2015-12-31 -8.22 7.38 5.12
2014-12-31 -1.81 6.53 8.18
  • Albireo Pharma has no debt.
  • Albireo Pharma currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Albireo Pharma has sufficient cash runway for more than 3 years based on current free cash flow.
  • Albireo Pharma has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 57.9% each year.
X
Financial health checks
We assess Albireo Pharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Albireo Pharma has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Albireo Pharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Albireo Pharma dividends.
If you bought €2,000 of Albireo Pharma shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Albireo Pharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Albireo Pharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:BDQM Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:BDQM Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Albireo Pharma has not reported any payouts.
  • Unable to verify if Albireo Pharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Albireo Pharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Albireo Pharma has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Albireo Pharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Albireo Pharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Albireo Pharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Albireo Pharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Ron Cooper
COMPENSATION $2,476,732
AGE 55
TENURE AS CEO 3.8 years
CEO Bio

Mr. Ronald H. W. Cooper, also known as Ron, has been the Chief Executive Officer and President of Albireo Pharma Inc. since July 2015. Mr. Cooper has spent more than 25 years at Bristol-Myers Squibb, where he worked in five different countries and held positions of increasing responsibility in sales, marketing and general management, culminating as President of Europe. At BMS, he was directly involved with numerous product successes, including Abilify®, Avapro®, Atripla®, Eliquis®, Orencia®, Pravachol®, Plavix®, Reyataz®, Sustiva®, Sprycel®, and Yervoy®. He has successfully completed more than a dozen business development transactions, including the creation of the first single tablet HIV/AIDS regimen Partnership. Mr. Cooper has been Director of Albireo Pharma Inc. since September 2015. Most recently, at Bristol-Myers Squibb Company, Mr. Cooper served as President, Europe from May 2010 until November 2015; President, Northern and Central Europe from April 2009 until April 2010; and Senior Vice President and General Manager, EU Markets from January 2008 until March 2009. He has been a Director of Genocea Biosciences, Inc. since June 9, 2016. Mr. Cooper earned his Bachelor’s degree in Chemistry and Business Administration from St. Francis Xavier University in Canada.

CEO Compensation
  • Ron's compensation has been consistent with company performance over the past year.
  • Ron's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Albireo Pharma management team in years:

0.8
Average Tenure
58
Average Age
  • The average tenure for the Albireo Pharma management team is less than 2 years, this suggests a new team.
Management Team

Ron Cooper

TITLE
CEO, President & Director
COMPENSATION
$2M
AGE
55
TENURE
3.8 yrs

Muffy Carter

TITLE
Chief Regulatory Officer
COMPENSATION
$1M
AGE
66
TENURE
2.4 yrs

Paresh Soni

TITLE
Consultant
COMPENSATION
$1M
AGE
58
TENURE
0.8 yrs

Per-Goran Gillberg

TITLE
Co-Founder & VP of Development

Jan Mattsson

TITLE
Chief Scientific Officer & MD (Sweden) and Co-Founder
COMPENSATION
$1M
AGE
54

Simon Harford

TITLE
CFO & Treasurer
TENURE
0.5 yrs

Jason Duncan

TITLE
General Counsel & Secretary
TENURE
0.8 yrs

Kristina Torfgård

TITLE
VP & Global Project Head

Patrick Horn

TITLE
Chief Medical Officer
AGE
63
TENURE
0.8 yrs

Pamela Stephenson

TITLE
Chief Commercial Officer
TENURE
0.1 yrs
Board of Directors Tenure

Average tenure and age of the Albireo Pharma board of directors in years:

2.4
Average Tenure
58
Average Age
  • The average tenure for the Albireo Pharma board of directors is less than 3 years, this suggests a new board.
Board of Directors

Dave Chiswell

TITLE
Chairman of the Board
COMPENSATION
$156K
AGE
65
TENURE
11.2 yrs

Ron Cooper

TITLE
CEO, President & Director
COMPENSATION
$2M
AGE
55
TENURE
3.6 yrs

Davey Scoon

TITLE
Director
COMPENSATION
$138K
AGE
71
TENURE
2.4 yrs

Mike Gutch

TITLE
Director
COMPENSATION
$155K
AGE
52
TENURE
3.5 yrs

Roger Jeffs

TITLE
Director
COMPENSATION
$73K
AGE
56
TENURE
1.6 yrs

Anne Klibanski

TITLE
Director
AGE
66
TENURE
0.8 yrs

Stephanie Okey

TITLE
Director
AGE
58
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
13. Mar 19 Sell Phase4 Partners Limited Company 05. Feb 19 27. Feb 19 -96,321 €24.12 €-2,218,751
X
Management checks
We assess Albireo Pharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Albireo Pharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat, an orally administered IBAT inhibitor for the treatment of chronic constipation and other functional diseases, and nonalcoholic steatohepatitis; and A3384 for the treatment of bile acid malabsorption. It has a license agreement with EA Pharma for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.

Details
Name: Albireo Pharma, Inc.
BDQM
Exchange: DB
Founded:
$330,953,803
12,026,025
Website: http://www.albireopharma.com
Address: Albireo Pharma, Inc.
10 Post Office Square,
Suite 502 South,
Boston,
Massachusetts, 02109,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM ALBO Common Stock Nasdaq Capital Market US USD 04. Nov 2016
DB BDQM Common Stock Deutsche Boerse AG DE EUR 04. Nov 2016
Number of employees
Current staff
Staff numbers
39
Albireo Pharma employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 23:07
End of day share price update: 2019/04/24 00:00
Last estimates confirmation: 2019/04/18
Last earnings filing: 2019/03/06
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.